AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03261466 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bifidobacterium breve BR03 and Bifidobacterium breve B632
Study NCT03261466 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Study NCT01083732 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dabigatran etexilate
Description: Experimental dose chosen based on age and weight
Study NCT02331485 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PICO + Acticoat group
Description: Comparison between Pico and Acticoat dressing change after 3 and 7 days with standard Mepor dressing change on daily basis.
Study NCT02331485 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PICO + Acticoat group
Description: Comparison between Pico and Acticoat dressing change after 3 and 7 days with standard Mepor dressing change on daily basis.
Study NCT01746576 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Use of impedance threshold device during spontaneous ventilation
Study NCT02593760 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered PO QD for up to 48 weeks.
Study NCT02593760 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ruxolitinib
Description: Ruxolitinib will be administered PO BID at a starting dose depending on the participants's baseline platelet count for up to 48 weeks.
Study NCT02593760 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: Ruxolitinib will be administered PO BID at a starting dose depending on the participants's baseline platelet count for up to 48 weeks.
Study NCT02593760 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vismodegib
Description: Vismodegib will be administered at a dose of 150 mg PO QD for up to 48 weeks.
Study NCT00564421 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: epinastine nasal spray, low concentration, low dose volume
Description: 2 sprays in each nostril, dosed twice a day
Study NCT00564421 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo nasal spray
Description: 2 sprays in each nostril, dosed twice a day
Study NCT00564421 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: epinastine nasal spray, low concentration, high dose volume
Description: 2 sprays in each nostril, dosed twice a day
Study NCT04751409 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Follow-Up
Description: Undergo limited follow-up
Study NCT04751409 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Imaging Technique
Description: Undergo imaging
Study NCT00564421 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: epinastine nasal spray, high concentration, low dose volume
Description: 2 sprays in each nostril, dosed twice a day
Study NCT00564421 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: epinastine nasal spray, high concentration, high dose volume
Description: 2 sprays in each nostril, dosed twice a day
Study NCT02240472 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Omission of axillary clearance
Description: The intervention is the omission of completion axillary clearance after the detection of sentinel node macrometastasis
Study NCT03528213 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Lactate light dose
Description: bolus 2.5ml/kg then 0.25ml/kg/h
Study NCT03528213 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Lactate high dose
Description: bolus 2.5ml/kg then 0.5ml/kg/h
Study NCT03528213 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Normal saline
Description: normal saline at physician discretion
Study NCT02042703 — intervention group
Intervention type: DEVICE
Intervention: anterior segment OCT
Study NCT03130894 — intervention group
Intervention type: OTHER
Intervention: Plasma TMAO concentration
Description: Plasma TMAO concentration
Study NCT04751409 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT04613765 — intervention group
Intervention type: BEHAVIORAL
Intervention: Measure adherence behaviors
Description: Conducted in the ambulatory setting of two Brussels hospitals, the MADESIO mixed-method study design combine sequentially a first quantitative explorative questionnaire-based study with a second in depth qualitative approach.~The first 4 visits questionnaire-based survey prospectively measures adherence to OAMs and identify associated risk factors in the two sub-groups of ambulatory patients with various haematological malignancies. A combination of validated self-reported measures able to measure medication taking behaviours, assess both intentional and unintentional adherence, identify associated risk factors was selected.~The second qualitative phase, based on the McGill Illness narrative interview design, deeper address patients' therapeutic adherence and subjective meanings.
Study NCT03005912 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Conventional acoustic telephony
Description: Quantification of speech comprehension by means of the Hochmair-Schulz-Moser sentence test.
Study NCT00099944 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vildagliptin
Study NCT00099944 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glimepiride
Description: Glimepiride 4 mg qd
Study NCT00099944 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Glimepiride
Description: Glimepiride 4 mg qd
Study NCT00099944 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: LAF237 placebo
Study NCT02349607 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-05089771 300mg
Description: PF-05089771 300 mg
Study NCT02349607 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-05089771 300 mg + pregabalin 300 mg
Description: PF-05089771 300 mg + pregabalin 300 mg
Study NCT02349607 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placeco
Study NCT02349607 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pregabalin 300 mg
Description: pregabalin 300 mg
Study NCT02349607 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ibuprofen 600 mg
Description: ibuprofen 600 mg
Study NCT01316757 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: cetuximab
Description: Given IV
Study NCT01316757 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: Given IV
Study NCT01316757 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Given IV
Study NCT04089930 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Immunogenicity
Description: anti-VZV IgG titer and cell-mediated immunity (VZV-stimulated T cell spots)
Study NCT01316757 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib hydrochloride
Description: Given PO
Study NCT01316757 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT00448851 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: inhaled allergen challenge
Description: Subjects will inhale gradually increasing concentrations of Dermatophagoides farinae until a 15% drop in FEV1 is noted
Study NCT00874640 — intervention group
Intervention type: BIOLOGICAL
Intervention: Gadobutrol (Gadovist, BAY86-4875)
Description: Patients with indication for a MRT or MR-Angiography and for whom the radiologist has decided to use the contrast medium gadobutrol
Study NCT02179736 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Restylane
Study NCT01915121 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Education Intervention
Description: 1-hour educational and training sessions. In this session, participant will be provided with information about bladder cancer treatment options, and training tools directly related to Bladder Cancer. In 4 to 5 days following the session, participants will be asked to schedule the time to talk about experience and how the intervention affects their treatment decision making and to answer some questions about the educational and training session they attended. Participants will then be called after 1-month, 3-month, and 6-month after their bladder cancer treatment to follow up.
Study NCT01915121 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Nutrition Intervention
Description: 1-hour educational and training sessions. In this session, participant will be provided with nutrition information directly related to Bladder Cancer recovery. In 4 to 5 days following the session, participants will be asked to schedule the time to talk about experience and how the intervention affects their treatment decision making and to answer some questions about the educational and training session they attended. Participants will then be called after 1-month, 3-month, and 6-month after their bladder cancer treatment to follow up.
Study NCT02111096 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2409021
Description: Administered orally
Study NCT02111096 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sitagliptin
Description: Administered orally
Study NCT02111096 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally
Study NCT02111096 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Administered orally
Study NCT02111096 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Metformin
Description: Administered orally
Study NCT02111096 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Administered orally
Study NCT02111096 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sulfonylurea
Description: Administered orally
Study NCT02111096 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sulfonylurea
Description: Administered orally
Study NCT02111096 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sulfonylurea
Description: Administered orally
Study NCT00294736 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tarceva
Description: Dose Escalation: 150-350+ mg/day
Study NCT00804219 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TBE vaccination and influenza vaccination
Description: FSME-Immun, 0,5 ml, i.m., 1x Inflexal 0,5 ml, i.m., 1x
Study NCT01419210 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pre-study Questionnaire
Description: Assess the interest level for various CAM topics through feedback received from the study participants
Study NCT01419210 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational Presentations
Description: Attend a two-hour presentation each week for four weeks
Study NCT01419210 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CAM Therapies
Description: Integrate the CAM topics of highest interest into participant's regular care
Study NCT01419210 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Post-study Questionnaire
Description: Examine the data to see if it supports recommending a larger, multi-site, integrative CAM program for other women with ovarian cancer
Study NCT03360513 — intervention group
Intervention type: OTHER
Intervention: general group
Description: The sample comprised maxillary and mandibular dental casts of 70 Caucasian Brazilian individuals (28 men and 42 women) with an average age of 16.4 years, all of which had natural normal occlusion with at least four of the six keys to normal occlusion. 14 The first item of the first key was considered essential for sample selection(Angle Class I molar relationship). Another inclusion criterion was that individuals should be at least 15 years of age with no odontogenic abnormalities and all permanent teeth in occlusion.
Study NCT01641900 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: eszopiclone
Description: 3 mg of eszopiclone for two consecutive nights (Baseline Night and Experimental Night). Sleep spindle density (primary outcome) is measured for both nights. Memory consolidation (secondary outcome) is measured over Experimental Night.
Study NCT01641900 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: placebo capsule for two consecutive nights. (Baseline Night and Experimental Night). Sleep spindle density (primary outcome) is measured for both nights. Memory consolidation (secondary outcome) is measured over Experimental Night.
Study NCT02310581 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buprenorphine Sublingual Spray
Description: Buprenorphine sublingual spray delivered via single 100 μL spray
Study NCT02310581 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo-matching buprenorphine sublingual spray delivered via single 100 μL spray
Study NCT02310581 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo-matching buprenorphine sublingual spray delivered via single 100 μL spray
Study NCT04178213 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Implantation of ADAPT 3D ALR
Description: The operation is performed through a median sternotomy and with the hemodynamic support of standard cardiopulmonary bypass (CBP). diseased leaflets are excised meticulously. Calcifications at the level of the annulus will be removed just like in any other aortic valve replacement procedure. The annulus will be sized and the appropriate 3D single piece valve will be chosen. The implant technique will consist out of one running suture line at the level of the annulus, followed by fixation of the 3 commissural parts against the aortic wall. Valve competence and function will be assessed visually, and by TEE immediately coming of bypass.
Study NCT01185041 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Watermelon Extract
Description: 6 weeks of watermelon extract taken in two doses of 3g each per day (6g per day)containing L-citrulline/L-arginine (4/2 g)
Study NCT01185041 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Watermelon Extract
Description: 6 weeks of watermelon extract taken in two doses of 3g each per day (6g per day)containing L-citrulline/L-arginine (4/2 g)
Study NCT03005912 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional bluetooth telephony
Description: Quantification of speech comprehension by means of the Hochmair-Schulz-Moser sentence test.
Study NCT03005912 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: VoIP acoustic telephony
Description: Quantification of speech comprehension by means of the Hochmair-Schulz-Moser sentence test.
Study NCT03005912 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: VoIP bluetooth telephony
Description: Quantification of speech comprehension by means of the Hochmair-Schulz-Moser sentence test.
Study NCT00446290 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel, Capecitabine and Oxaliplatin
Study NCT00040664 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ritonavir
Description: ritonavir oral capsules or oral solution
Study NCT00040664 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fosamprenavir
Description: fosamprenavir oral suspension or tablet
Study NCT03049280 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transoral robotic surgery
Description: Transoral robotic surgery for T1 \& T2 oropharyngeal cancers
Study NCT02421276 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Phlebotomy
Description: White blood cell analysis: Subtypes of white blood cells will be counted by flow cytometry
Study NCT03763591 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Trauma Systems Therapy for Refugees Group Intervention
Description: Psychological skills group for youth of refugee and immigrant backgrounds.
Study NCT02101476 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Percocet
Description: 10mg/650mg
Study NCT02101476 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Xartemis
Description: 15mg/650mg
Study NCT03504150 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SPHERE
Description: Comprehensive Internet-based CBT program with no human support
Study NCT03504150 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PRISM
Description: Brief Internet-based CBT program with no human support
Study NCT00447642 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LX201
Description: LX201 was a novel sustained-release silicone implant containing 30% cyclosporine A by weight.~LX201 was available in two different lengths, 0.50 and 0.75 inch. Each implant is 0.08 inch wide and 0.04 inch in height. The implants are flat on one side (the posterior surface, which is applied to the episclera) and the anterior surface and ends were rounded.
Study NCT01115894 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naltrexone
Description: 100 mg oral dosage daily for 12 weeks
Study NCT01115894 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Modified Behavioral Self-Control Psychotherapy
Description: Moderation- and cognitive-behaviorally-based psychotherapy. Treatment goal of moderation of alcohol consumption. 12 weekly, 1-hour sessions.
Study NCT01115894 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Behavioral Compliance Enhancement Therapy
Description: Brief supportive counseling to enhance compliance with medication and encourage goal-setting concerning alcohol consumption.
Study NCT01115894 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo
Study NCT01441908 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pravastatin
Description: 40mg or 80mg dose 28 days for 6 month period
Study NCT03523793 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Clinical Practice Guideline Implementation
Description: The Study team will use several methods from the implementation strategy taxonomy of the Effective Practice and Organization of Care (EPOC) classification system to improve our likelihood for successful neck and low back pain implementation consisting of: 1) educational materials, workshops and outreach visits from trainers; 2) external consultant testimonials; 3) iterative quality improvement processes (including ongoing analysis of clinician feedback to improve process); 4) routine collection of patient reported outcomes to engage discussion among clinician groups and outpatient division leaders) and 5) local organization consensus process (including feedback from key outpatient division stakeholders).
Study NCT00447642 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo was a silicone implant 0.75 inch in length. It contained no cyclosporine A
Study NCT03523793 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care
Description: Considering the stepped wedge design with a 12-week washout phase, clinics will be providing standard physical therapy prior to receiving clinical practice guideline training.
Study NCT03479177 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High Intensity Interval Training
Description: The exercise sessions will be based on exercises the participant can confidentially engage in (regular push-ups vs. knee push-ups vs. wall push-ups). The goal will be to engage in three exercise sessions per week. The participants will receive weekly telephone calls during the first month and bi-weekly calls during months 2 and 3. The exercise counselor will also engage in dialogue that will motivate the participant to exercise.
Study NCT03222934 — intervention group
Intervention type: DEVICE
Intervention: multislice computed tomography
Description: radiological diagnosis of the status and variations in the sphenoid sinus
Study NCT03768466 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brand Name: Targin®
Description: Brand Name: Targin® Generic name: Oxycodone/Naloxone dosage form: Oral
Study NCT01493882 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Form = tablet, route = oral administration, once daily from Week 0 to Week 24 for Part 1 and Part 2
Study NCT01493882 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-39758979 30 mg/d
Description: Unit = mg, number = 30, form = tablet, route = oral administration, once daily from Week 0 to Week 24 only for Part 2
Study NCT01493882 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-39758979 100 mg/d
Description: Unit = mg, number = 100, form = tablet, route = oral administration, once daily from Week 0 to Week 24 only for Part 2
Study NCT03792282 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Time Restricted Feeding
Description: Participants will receive a diet of 1200-1500kcal/d and be instructed to eat only during a window of 8 hours (Finishing the last meal before 4pm).
Study NCT03792282 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Participants receive a general lifestyle counseling.
Study NCT01493882 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-39758979 300 mg/d
Description: Unit = mg, number = 300, form = tablet, route = oral administration, once daily from Week 0 to Week 24 for Part 1 and Part 2
Study NCT02199626 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Second generation of colon capsule endoscopy (GIVEN IMAGING)
Study NCT04919850 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Saccharomyces boulardii and SOD
Description: A complex of 250 mg of Saccharomyces boulardii and 500 IU SOD to be assumed twice/day for 8 weeks at mealtimes